Overview | Index | Requesting Use of Contract Resources | DAIDS Home

The following NIAID contract resources are available to assist investigators in evaluating novel therapies and topical microbicides in simian animal models.

In Vitro Efficacy Evaluations

• Potential therapeutic agents and microbides are evaluated for cytotoxicity and for efficacy against appropriate strains of SIV and SHIV prior to evaluation in vivo
• Therapeutic agents and microbides can be evaluated either alone or in combination with other agents

In Vivo Efficacy Evaluations

• Simian models employ macaques infected with SIV or SHIV and use a variety of virologic and immunologic parameters to measure efficacy
• Therapeutic agents and microbides can be evaluated either alone or in combination with other agents
• Both antiviral and immune-based therapies can be evaluated
• Limited pharmacokinetic and toxicology evaluations and studies to determine optimal routes and schedules of administration can be performed

Sample Contractor Publications

• C.-C. Tsai, et al. 1995. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 270:1197-1199.
• L.N. Martin, et al. 1997. Cyclosporin A modulation of early virological and immunological events during primary simian immunodeficiency virus infection in rhesus monkeys. J. Infect. Dis. 176:374-383.

Accessing These Resources

For further information regarding evaluations of systemic therapies in the SIV or SHIV model please contact Dr. Frosso Voulgaropoulou (phone: 301-451-2704; e-mail: fvoulgaropoulou@niaid.nih.gov ).

For further information regarding evaluations of topical microbicides in the SIV or SHIV model please contact Dr. Kailash Gupta (phone: 301-435-3724; e-mail: kgupta@niaid.nih.gov).